

9904263-2

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A01N 37/10, C07C 69/16	A1	(11) International Publication Number: WO 98/39965 (43) International Publication Date: 17 September 1998 (17.09.98)
(21) International Application Number: PCT/US98/04756 (22) International Filing Date: 11 March 1998 (11.03.98) (30) Priority Data: 08/814,366 11 March 1997 (11.03.97) US (71) Applicant: BEACON LABORATORIES L.L.C. [US/US]; Suite 303, Wayne Plaza I, 145 Route 46 West, Wayne, NJ 07470 (US). (72) Inventors: NEISS, Edward; 200 Charter Oak Drive, New Cannan, CT 06840 (US); LOEV, Bernard; 19 Candlewood Terrace, Medford, NJ 08500 (US). (74) Agents: WILSON, M., Lisa et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF (57) Abstract This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of a tumor suppressor gene and inducing tolerance to an antigen. The methods of the invention use unsaturated oxyalkylene esters.		